Kemia believes that KC706 may hold the potential to treat conditions such as rheumatoid arthritis, psoriasis, asthma, chronic obstructive pulmonary disorder, and certain metabolic and cardiovascular diseases. A
The double-blind, placebo-controlled trial enrolled 60 patients at 10 clinical sites in the US. Patients enrolled in the trial had a mean FEV1 (forced expiratory volume in one
Acthar Gel (repository corticotropin injection) is a natural adrenocorticotropic hormone, or ACTH, designed to provide a prolonged release after intramuscular or subcutaneous injection. It is currently indicated for
According to Merck, preliminary analyses indicate that the program, named MEDAL, showed the rate of confirmed thrombotic cardiovascular (CV) events to be similar between Arcoxia and diclofenac. However,
The Psychopharmacologic Drugs Advisory Committee meeting was scheduled for September 7, 2006 to provide a forum for FDA advisors to discuss and review data included in Wyeth’s new
The trial compares the survival of patients treated with tesmilifene combined with epirubicin/cyclophosphamide to epirubicin/cyclophosphamide alone in women with rapidly progressing metastatic and/or recurrent breast cancer. The trial,
Denavir (penciclovir cream) 1% is a topical antiviral prescription medication indicated for the treatment of herpes labialis, also known as cold sores, in adults. This is the only
In this open-label trial the histone deacetylases (HDAC) inhibitor MGCD0103 will be given orally at a dose of 110mg, three times per week, to patients with Hodgkin’s lymphoma
Innovive has renamed the compound INNO-206 and plans to initiate a phase II study in a solid tumor indication shortly. INNO-206 is a prodrug of the commonly used
FibroGen is already conducting multiple phase II clinical studies of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors that stimulate erythropoiesis for the treatment of anemia, including the company’s lead
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.